A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms
Antimicrobial Agents and Chemotherapy · 04.02.2026 · 70 (2)
DOI: 10.1128/aac.00782-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.02.2026. Verfasst von Ramya Mahadevan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Titus Family Department of Clinical Practice, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, L…. Hauptthemen laut MEDLINE: Polymyxin B, Klebsiella pneumoniae, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Increased resistance to β-lactams/β-lactamase inhibitors by mutations in β-lactamase genes, porins, and efflux pumps complicates the management of carbapenem-resistant Klebsiella pneumoniae (CRKP). Polymyxin B (PMB)-based combination therapy is the best alternative treatment for middle and low-income countries that cannot access the latest medicines. It is crucial to know both phenotypic and genotypic characteristics of a pathogen to understand the killing effect of each drug and its combinations. Hence, our objective was to incorporate mechanistic insights gained from resistance mechanisms of each isolate to develop a mechanism-based pharmacokinetic/pharmacodynamic model. Six clinical CRKP isolates with diverse genotypic resistance expressing bla KPC , bla NDM , porin, and mgrB mutations were used for static concentration time kill (SCTK) assays to evaluate the rate and extent of killing by monotherapy, double and triple combinations using PMB (0.5–64 mg/L), meropenem (10–120 mg/L), and fosfomycin (75–500 mg/L). Isolate BRKP28 expressed non-functional MgrB (a regulatory protein) and high-level phenotypic resistance (PMB MIC: >128 mg/L). In line with the observed resistance, the model estimated that BRKP28 had a reduced maximum killing rate constant for PMB (3.61 h⁻¹) relative to other isolates. The mechanistic synergy of PMB, due to outer membrane disruption, was incorporated into three isolates with porin mutations. PMB demonstrated 83%–88% mechanistic synergy with meropenem and 81%–98% with fosfomycin. The model further estimated that a very low concentration of PMB (0.49–0.64 mg/L) was sufficient to achieve 50% of the maximum synergy. Simulations using population pharmacokinetic models showed that combination therapy of PMB (1 mg/kg q12h) and fosfomycin (8 g q8h) achieved >73% reduction in area under the bacterial load-versus-time curve across four isolates. The triple combination therapy achieved a 67.7% reduction in non-carbapenamase producing isolate. These findings demonstrates that a low PMB dosing regimen (1 mg/kg q12h) can produce synergistic effects in combination therapy and may be effective in managing infections caused by CRKP, including PMB resistant isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Titus Family Department of Clinical Practice, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
- Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
- College of Pharmacy, Fujian Medical University, Fuzhou, People's Republic of China.
- Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
- Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, Antimicrobial Service of the National Institute of Infectious Diseases (ANLIS Dr. Carlos G. Malbrán), Buenos Aires, Argentina.
ORCID-Profile: Ramya Mahadevan, Hongqiang Qiu, Maria Soledad Ramirez, Robert A Bonomo, Gauri G Rao
Zitieren
APA
Mahadevan, R., Garcia, E., Sharma, R., Qiu, H., Elsheikh, A., Parambi, R., Abboud, C. S., Pasteran, F., Ramirez, M. S., Kaye, K. S., Bonomo, R. A., & Rao, G. G. (2026). A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms. Antimicrobial Agents and Chemotherapy, 70(2). https://doi.org/10.1128/aac.00782-25
Vancouver
Mahadevan R, Garcia E, Sharma R, Qiu H, Elsheikh A, Parambi R, et al. A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms. Antimicrobial Agents and Chemotherapy. 2026;70(2). doi:10.1128/aac.00782-25
BibTeX
@article{Mahadevan2026,
author = {Mahadevan, Ramya and Garcia, Estefany and Sharma, Rajnikant and Qiu, Hongqiang and Elsheikh, Ahmed and Parambi, Robert and Abboud, Cely Saad and Pasteran, Fernando and Ramirez, Maria Soledad and Kaye, Keith S and Bonomo, Robert A and Rao, Gauri G},
title = {A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {2},
doi = {10.1128/aac.00782-25}
}
EUVIMED